This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Canagliflozin
SGLT2 inhibitor with mild SGLT1 activity.
Aliases (3)
Overview
What is Canagliflozin?
SGLT2 inhibitor with mild SGLT1 activity. CANVAS amputation signal (boxed warning history). Class-similar to dapagliflozin/empagliflozin otherwise.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.